TRIM66 and prostate cancer: Notably, our results further uncovered the oncogenic activities of IL‐2 in prostate cancer cells, wherein IL‐2 was subjected to TRIM66‐positive regulation, and IL‐2 silencing greatly compromised cell proliferation, invasion and migration.